Johnson & Johnson (JNJ)
(Delayed Data from NYSE)
$164.99 USD
-2.37 (-1.42%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $164.96 -0.03 (-0.02%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$164.99 USD
-2.37 (-1.42%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $164.96 -0.03 (-0.02%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth F Momentum F VGM
Zacks News
Should Invesco S&P 500 Low Volatility ETF (SPLV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPLV
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?
by Zacks Equity Research
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
STERIS (STE) Q4 Earnings Beat Estimates, Gross Margin Falls
by Zacks Equity Research
Heading into fiscal 2024, STERIS (STE) expects many of its fiscal 2023 challenges to abate, including procedure volumes and supply chain constraints.
Haemonetics (HAE) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Amid a challenging economic environment, Haemonetics (HAE) delivers impressive fiscal fourth-quarter organic revenues, led by the stellar performance across the Plasma and Hospital business.
Should Vanguard High Dividend Yield ETF (VYM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VYM
Alcon (ALC) Q1 Earnings Surpass Estimates, 23' EPS View Up
by Zacks Equity Research
Alcon (ALC) Q1 revenues were driven by strong consumables and equipment sales.
Here's Why You Should Retain Walgreens Boots (WBA) For Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA) on consistent partnership growth and a strong focus on strategic execution.
Charles River (CRL) Q1 Earnings Top Estimates, View Narrowed
by Zacks Equity Research
Charles River (CRL) registers robust growth in small research models, research model services and the Cell Solutions business.
NuVasive (NUVA) Q1 Earnings Beat Estimates, Margins Fall
by Zacks Equity Research
NuVasive's (NUVA) strong sales across the U.S. Spinal Hardware and U.S. Surgical Support businesses instill optimism.
Syneos Health (SYNH) Tops Q1 Earnings, Announces Merger Plan
by Zacks Equity Research
Syneos Health's (SYNH) first-quarter 2023 earnings and revenues beat estimates. The company enters into a definitive merger agreement to be acquired by a private investment consortium.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Halozyme (HALO) Q1 Earnings Disappoint, Revenues Rise Y/Y
by Zacks Equity Research
Halozyme (HALO) first-quarter earnings and revenues miss estimates. The company reiterates its guidance for 2023.
SmileDirectClub (SDC) Q1 Earnings Miss, Gross Margin Up
by Zacks Equity Research
SmileDirectClub (SDC) Q1 revenues are affected by persistent macroeconomic headwinds.
Emergent (EBS) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Emergent (EBS) reports wider-than-expected first-quarter loss. The company updates its 2023 guidance for selected categories.
Exact Sciences (EXAS) Q1 Earnings Top, Sales View Raised
by Zacks Equity Research
The upside in Exact Sciences' (EXAS) screening revenues is primarily coming from broad-based momentum in Cologuard adoption.
Pharma ETFs Gain Post Q1 Earnings
by Sweta Killa
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. As such, pharma ETFs have been in the green over the past month.
Henry Schein (HSIC) Q1 Earnings Miss, Operating Margin Dips
by Zacks Equity Research
Henry Schein's (HSIC) first-quarter results largely reflect lower contributions from the sales of PPE products and COVID-19 test kits.
Omnicell's (OMCL) New Acquisitions Aid Growth, Cost Woes Stay
by Zacks Equity Research
Omnicell (OMCL) remains well-positioned to meet pharmacy and hospital needs, backed by the recent acquisitions and expansion of its advanced services solutions.
Bruker's (BRKR) New Buyout to Advance Digital Transformation
by Zacks Equity Research
Bruker's (BRKR) IDS division expands its unique vendor-agnostic software solutions portfolio by integrating ZONTAL with the Mestrelab Research and Arxspan scientific software solutions.
Here's Why You Should Retain Abbott (ABT) Stock For Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) on continued growth in the core Diagnostics arm.
Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWX
Teleflex (TFX) Q1 Earnings Top Estimates, 2023 Sales View Up
by Zacks Equity Research
Teleflex (TFX) registers growth across the majority of its businesses, including double-digit increases in interventional and surgical revenues in Q1.
Globus Medical (GMED) Q1 Earnings Beat, Operating Margin Dips
by Zacks Equity Research
The significant year-over-year surge in Globus Medical's (GMED) Enabling Technologies sales is driven by ongoing demand for the company's robotics and imaging system technologies.